ADMA Q4 2020 Earnings — ADMA Biologics, Inc. Revenue & Financial Results | Market Cap Arena

ADMAADMA Biologics, Inc.

$4B

Q4 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$14M+15.9% YoY

Gross Profit

-$5M-36.9% margin

Operating Income

-$17M-123.4% margin

Net Income

-$19M-139.1% margin

EPS (Diluted)

$-0.20

QoQ Revenue Growth

+35.8%

Cash Flow

Operating Cash Flow

-$32M

Free Cash Flow

-$36M

Stock-Based Comp.

$688,182

Balance Sheet

Total Assets

$208M

Total Liabilities

$119M

Stockholders' Equity

$88M

Cash & Equivalents

$56M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$14M	$12M	+15.9%
Gross Profit	-$5M	$345,446	-1592.3%
Operating Income	-$17M	-$8M	-120.0%
Net Income	-$19M	-$11M	-83.8%